Prasugrel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Nov 1, 2011 → Nov 1, 2012
NCT ID
NCT01476696About Prasugrel
Prasugrel is a phase 2 stage product being developed by Daiichi Sankyo for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01476696. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03672097 | Approved | Completed |
| NCT01476696 | Phase 2 | Completed |
| NCT01178099 | Phase 1 | Completed |
Competing Products
20 competing products in Sickle Cell Disease